Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia

Clinical Trial ID NCT01039363

Rank	Title	Journal	Year	PubWeight™‹?›
1	Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.	Nat Rev Drug Discov	2002	6.97
2	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.	Blood	2007	3.14
3	Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.	Clin Cancer Res	2001	2.35
4	Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.	Blood	2002	1.29
5	Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.	Blood	2006	1.22
6	The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.	Leukemia	2006	1.08
7	Histone deacetylase inhibitors: clinical implications for hematological malignancies.	Clin Epigenetics	2010	0.76
8	Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.	Eur J Haematol	2007	0.75